Literature DB >> 30778836

NF1 Somatic Mutation in Dystrophic Scoliosis.

Rebecca L Margraf1, Chad VanSant-Webb1, Rong Mao1,2, David H Viskochil3,4, John Carey3,4, Heather Hanson3, Jacques D'Astous4, Allie Grossmann2, David A Stevenson5.   

Abstract

Scoliosis is a common manifestation of neurofibromatosis type 1, causing significant morbidity. The etiology of dystrophic scoliosis in neurofibromatosis type 1 is not fully understood and therapies are lacking. Somatic mutations in NF1 have been shown in tibial pseudarthrosis providing rationale for similar processes in neurofibromatosis type 1-associated dystrophic scoliosis. Spinal samples from surgical procedures with matched peripheral blood of two individuals with neurofibromatosis type 1 and dystrophic scoliosis were obtained and DNA extracted. Next generation sequencing of various spinal sections as well as the germline/blood sample were performed using a RASopathy gene panel (includes the NF1 gene). Variants were compared between the spinal tissue samples and the germline data. In addition, the next generation sequencing allele frequency data were used to detect somatic loss of heterozygosity. All samples had a detected potentially inactivating NF1 germline mutation. Both individuals demonstrated an allelic imbalance inclusive of NF1 in the next generation sequencing data. In addition, for the same two individuals, there was an increase in the % variant reads for the germline mutation in some of the surgical spinal samples corresponding to the allelic imbalance. Contra analysis did not show any deletion in Chromosome 17 next generation sequencing data. Microarray analysis verified somatic copy neutral loss of heterozygosity for these two individuals for the majority of the chromosome 17 q-arm, inclusive of the NF1 gene. These results suggest that the cause of dystrophic scoliosis is multifactorial and that a somatic NF1 mutation contributes to the etiology.

Entities:  

Keywords:  NF1; Neurofibromatosis type 1; Scoliosis; Somatic mutation; Spine

Mesh:

Substances:

Year:  2019        PMID: 30778836     DOI: 10.1007/s12031-019-01277-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  14 in total

1.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

Review 2.  Osseous manifestations of neurofibromatosis in childhood.

Authors:  A H Crawford; N Bagamery
Journal:  J Pediatr Orthop       Date:  1986 Jan-Feb       Impact factor: 2.324

Review 3.  Pitfalls of spinal deformities associated with neurofibromatosis in children.

Authors:  A H Crawford
Journal:  Clin Orthop Relat Res       Date:  1989-08       Impact factor: 4.176

4.  Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1.

Authors:  David W Sant; Rebecca L Margraf; David A Stevenson; Allie H Grossmann; David H Viskochil; Heather Hanson; Melanie D Everitt; Jonathan J Rios; Florent Elefteriou; Theresa Hennessey; Rong Mao
Journal:  J Med Genet       Date:  2015-01-22       Impact factor: 6.318

5.  Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis Type 1 Cohort with Tibial Pseudarthrosis.

Authors:  Rebecca L Margraf; Chad VanSant-Webb; David Sant; John Carey; Heather Hanson; Jacques D'Astous; Dave Viskochil; David A Stevenson; Rong Mao
Journal:  J Mol Diagn       Date:  2017-05       Impact factor: 5.568

6.  Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Authors:  Nandina Paria; Tae-Joon Cho; In Ho Choi; Nobuhiro Kamiya; Kay Kayembe; Rong Mao; Rebecca L Margraf; Gerlinde Obermosser; Ila Oxendine; David W Sant; Mi Hyun Song; David A Stevenson; David H Viskochil; Carol A Wise; Harry K W Kim; Jonathan J Rios
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

7.  Prevalence of scoliosis in neurofibromatosis.

Authors:  B A Akbarnia; K R Gabriel; E Beckman; D Chalk
Journal:  Spine (Phila Pa 1976)       Date:  1992-08       Impact factor: 3.468

8.  Pathophysiology of spinal deformities in neurofibromatosis. An analysis of seventy-one patients who had curves associated with dystrophic changes.

Authors:  H Funasaki; R B Winter; J B Lonstein; F Denis
Journal:  J Bone Joint Surg Am       Date:  1994-05       Impact factor: 5.284

9.  Dystrophic spinal deformities in a neurofibromatosis type 1 murine model.

Authors:  Steven D Rhodes; Wei Zhang; Dalong Yang; Hao Yang; Shi Chen; Xiaohua Wu; Xiaohong Li; Xianlin Yang; Khalid S Mohammad; Theresa A Guise; Amanda L Bergner; David A Stevenson; Feng-Chun Yang
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

10.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

View more
  6 in total

1.  Identification of Copy Number Variants in a Southern Chinese Cohort of Patients with Congenital Scoliosis.

Authors:  Wenjing Lai; Xin Feng; Ming Yue; Prudence W H Cheung; Vanessa N T Choi; You-Qiang Song; Keith D K Luk; Jason Pui Yin Cheung; Bo Gao
Journal:  Genes (Basel)       Date:  2021-08-05       Impact factor: 4.096

2.  Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques.

Authors:  Rafay Ahmed; Sasidhar Uppuganti; Shrey Derasari; Joshua Meyer; Jacquelyn S Pennings; Florent Elefteriou; Jeffry S Nyman
Journal:  J Bone Miner Res       Date:  2022-07-12       Impact factor: 6.390

3.  Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.

Authors:  Schuyler Tong; W Patrick Devine; Joseph T Shieh
Journal:  JCO Precis Oncol       Date:  2022-05

Review 4.  MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.

Authors:  Anja Harder
Journal:  Biomark Res       Date:  2021-04-16

5.  Prenatal Diagnosis of 17p11.2 Copy Number Abnormalities Associated With Smith-Magenis and Potocki-Lupski Syndromes in Fetuses.

Authors:  Meiying Cai; Xianguo Fu; Liangpu Xu; Na Lin; Hailong Huang
Journal:  Front Genet       Date:  2021-12-21       Impact factor: 4.599

6.  A molecular basis for neurofibroma-associated skeletal manifestations in NF1.

Authors:  Yun Ma; Andrea M Gross; Eva Dombi; Alexander Pemov; Kwangmin Choi; Katherine Chaney; Steven D Rhodes; Steven P Angus; Noah Sciaky; D Wade Clapp; Nancy Ratner; Brigitte C Widemann; Jonathan J Rios; Florent Elefteriou
Journal:  Genet Med       Date:  2020-06-30       Impact factor: 8.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.